Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (21-30 of 111) with videos related to

Pageof 12
Sort By:
BJU International|December 19, 2016
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studiesMatthias Oelke, Adrian Wagg, Yasushi Takita, et al.
Cleveland Clinic Journal of Medicine|April 14, 2005
The impact of stress urinary incontinence on sexual activity in womenMatthew D Barber, Sherie A Dowsett, Karen J Mullen, et al.
Neurourology and Urodynamics|January 24, 2012
Urinary incontinence during pregnancy and 1 year after delivery in primiparous women compared with a control group of nulliparous womenBent Brandt Hansen, Jens Svare, Lars Viktrup, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|July 16, 2004
Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary IncontinenceLars Viktrup, Beth A. Pangallo, Michael J. Detke, et al.
The Journal of Urology|August 30, 2008
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding studyClaus G Roehrborn, Kevin T McVary, Albert Elion-Mboussa, et al.
Expert Opinion on Drug Safety|November 1, 2005
Safety and adverse event profile of duloxetineJoachim F Wernicke, James Gahimer, Ilker Yalcin, et al.
Advances in Therapy|December 16, 2024
Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims AnalysisGilwan Kim, Margaret Hoyt, Armen Zakharyan, et al.
Therapeutic Advances in Urology|October 2, 2015
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of actionOsamu Yokoyama, Yasuhiko Igawa, Masayuki Takeda, et al.
Current Medical Research and Opinion|August 27, 2013
Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness SurveyShonda A Foster, Kathy Annunziata, Emily F Shortridge, et al.
European Urology|September 29, 2012
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasiaFrançois Giuliano, Stefan Ückert, Mario Maggi, et al.
Pageof 12

Showing results (21-30 of 111) with videos related to

Sort By:
Pageof 12
BJU International|December 19, 2016
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studiesMatthias Oelke, Adrian Wagg, Yasushi Takita, et al.
Cleveland Clinic Journal of Medicine|April 14, 2005
The impact of stress urinary incontinence on sexual activity in womenMatthew D Barber, Sherie A Dowsett, Karen J Mullen, et al.
Neurourology and Urodynamics|January 24, 2012
Urinary incontinence during pregnancy and 1 year after delivery in primiparous women compared with a control group of nulliparous womenBent Brandt Hansen, Jens Svare, Lars Viktrup, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|July 16, 2004
Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary IncontinenceLars Viktrup, Beth A. Pangallo, Michael J. Detke, et al.
The Journal of Urology|August 30, 2008
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding studyClaus G Roehrborn, Kevin T McVary, Albert Elion-Mboussa, et al.
Expert Opinion on Drug Safety|November 1, 2005
Safety and adverse event profile of duloxetineJoachim F Wernicke, James Gahimer, Ilker Yalcin, et al.
Advances in Therapy|December 16, 2024
Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims AnalysisGilwan Kim, Margaret Hoyt, Armen Zakharyan, et al.
Therapeutic Advances in Urology|October 2, 2015
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of actionOsamu Yokoyama, Yasuhiko Igawa, Masayuki Takeda, et al.
Current Medical Research and Opinion|August 27, 2013
Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness SurveyShonda A Foster, Kathy Annunziata, Emily F Shortridge, et al.
European Urology|September 29, 2012
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasiaFrançois Giuliano, Stefan Ückert, Mario Maggi, et al.
Pageof 12